The Defence Research and Development Organisation (DRDO) will get 2 percent royalty from Dr. Reddy’s Laboratory (DRL) on the sale of anti-COVID drug 2-DG, Minister of State for Defence Ajay Bhatt said on Wednesday.
In a written reply to a question in the Lok Sabha, Bhatt said the DRDO developed the technology along with DRL, Hyderabad. The pricing is decided by DRL. The actual price fixed by DRL is Rs 990 per sachet.
“DRDO will get 2 percent royalty on the sale of 2-DG in the Indian market as per Transfer of Technology agreement,” Bhatt said.
The Drugs Controller General of India (DCGI) approved the 2 deoxy-D-glucose (2-DG) drugs for emergency use as an additional therapy in moderate to severe COVID patients in early May.
The Defence Ministry on May 8 had said that the clinical trials of 2-DG showed that it speeds up the recovery of hospitalised patients and reduces supplement oxygen dependence.
